Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. (Q46980729)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2007

Language	Label	Description	Also known as
English	Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.	scientific article published in October 2007

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

7

object named as

Beth Levine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Ping Zhou

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Joanne Chou

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Julie Teruya-Feldstein

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lilian Reich

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Hani Hassoun

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Daniel A Filippa

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Elyn Riedel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Tarun Kewalramani

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Michael D Stubblefield

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Martin Fleisher

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Stephen Nimer

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Raymond L Comenzo

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

British Journal of Haematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

139

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

224-233

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17897298%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Autologous stem cell transplantation for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Transplantation for amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06783.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46980729&oldid=1587282326"